Plain-English translation of NCT01906385 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called 186Rhenium Nanoliposomes (186RNL) for people with gliomas — aggressive brain tumors that have come back after earlier treatment. The medication is a radioactive substance delivered directly into the tumor through a special catheter placed during surgery. Researchers want to find the right dose and learn whether this treatment is safe and can help control the tumor.
Standard treatments for recurring brain tumors have limited effectiveness, and many patients run out of good options. This medication is designed to deliver radiation directly to the tumor to try to stop it from growing, offering patients with recurrent gliomas a potentially new way to fight their cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have a catheter surgically placed into your brain tumor, through which doctors will administer a single dose of the medication. You will then be monitored closely for up to 3 years with regular visits, imaging scans, and blood tests to track how well the treatment works and watch for any side effects. The trial has two phases: the first phase tests different dose levels to find the safest amount, and the second phase treats more patients with the dose that worked best.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States